Clinical trial
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
NCT00153062 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00153062 |
|---|---|
| Title | PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes |
| Official title | PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Collaborators | GlaxoSmithKline Industry Bayer |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Stroke |
| Intervention type | Drug |
| Interventions | Aggrenox, Clopidogrel placebo, Micardis, Aggrenox placebo, Clopidogrel, Micardis placebo |
| Enrollment | 20,332 |
| Start date | Aug 1, 2003 |
| Primary completion | Apr 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | May 13, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, El Salvador, Finland, France, Germany and 24 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: